Bio-Techne (TECH) Financials

$46.66 -2.87 (-5.79%)

Closing price 04:00 PM Eastern

Extended Trading

$46.70 +0.04 (+0.08%)

As of 05:48 PM Eastern

Annual Income Statements for Bio-Techne

This table shows Bio-Techne's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Net Income / (Loss) Attributable to Common Shareholders	168	285	272	140	229	96	126	76	104	108
Consolidated Net Income / (Loss)	168	285	263	140	229	96	126	76	104	108
Net Income / (Loss) Continuing Operations	168	285	263	140	229	96	126	76	104	108
Total Pre-Tax Income	186	339	301	148	276	112	126	112	147	154
Total Operating Income	207	299	297	237	157	147	136	121	151	147
Total Gross Profit	770	770	756	633	483	473	432	375	337	307
Total Revenue	1,159	1,137	1,106	931	739	714	643	563	499	452
Operating Revenue	1,159	1,137	1,106	931	739	714	643	563	499	452
Total Cost of Revenue	389	367	349	298	255	241	211	188	162	145
Operating Cost of Revenue	389	367	349	298	255	241	211	188	162	145
Total Operating Expenses	563	471	460	396	326	327	296	254	186	160
Selling, General & Admin Expense	466	378	373	325	261	264	241	200	141	119
Research & Development Expense	97	92	87	71	65	62	55	54	45	41
Total Other Income / (Expense), net	-21	40	4.80	-89	119	-35	-10	-8.62	-3.11	7.14
Interest Expense	16	11	11	14	19	22	10	7.36	1.75	1.54
Interest & Investment Income	3.32	3.41	0.79	0.47	0.61	0.57	0.41	0.30	0.25	0.63
Other Income / (Expense), net	-8.58	48	15	-76	138	-14	-0.45	-1.57	-1.61	8.05
Income Tax Expense	18	53	38	8.59	47	16	-0.20	36	43	46
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.18	-8.95	-0.83	0.00	0.00	-	-	-	-
Basic Earnings per Share	$1.07	$1.81	$1.73	$0.91	$6.00	$2.54	$3.36	$2.04	$2.81	$2.90
Weighted Average Basic Shares Outstanding	157.71M	157.18M	156.87M	154.99M	38.20M	37.78M	37.48M	37.31M	37.19M	37.10M
Diluted Earnings per Share	$1.05	$1.76	$1.66	$0.87	$5.82	$2.47	$3.31	$2.03	$2.80	$2.89
Weighted Average Diluted Shares Outstanding	160.77M	161.86M	164.11M	161.93M	39.40M	38.89M	38.06M	37.50M	37.33M	37.23M
Weighted Average Basic & Diluted Shares Outstanding	158.60M	158.17M	39.21M	39.08M	38.55M	37.80M	37.50M	37.30M	37.20M	37.20M
Cash Dividends to Common per Share	$0.32	$0.32	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$1.27

This table shows Bio-Techne's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	23	35	34	41	49	27	51	75	70	50	90
Consolidated Net Income / (Loss)	23	35	34	41	49	27	51	75	70	50	90
Net Income / (Loss) Continuing Operations	23	35	34	41	49	27	51	75	70	50	90
Total Pre-Tax Income	38	43	40	42	61	33	50	88	80	66	104
Total Operating Income	39	47	40	46	67	38	56	95	80	68	56
Total Gross Profit	215	194	183	203	205	177	185	205	202	183	180
Total Revenue	316	297	289	306	303	273	277	301	294	272	270
Operating Revenue	316	297	289	306	303	273	277	301	294	272	270
Total Cost of Revenue	102	103	106	103	99	96	92	97	92	88	90
Operating Cost of Revenue	102	103	106	103	99	96	92	97	92	88	90
Total Operating Expenses	176	146	143	158	138	139	129	110	122	115	123
Selling, General & Admin Expense	151	121	119	134	112	116	105	87	99	93	99
Research & Development Expense	25	25	24	24	26	23	24	23	23	22	24
Total Other Income / (Expense), net	-0.43	-4.54	0.18	-4.16	-5.91	-4.62	-6.30	-6.21	-0.02	-1.46	47
Income Tax Expense	16	7.99	6.57	1.07	12	5.92	-1.44	13	9.98	16	14
Basic Earnings per Share	$0.14	$0.22	$0.21	$0.26	$0.31	$0.17	$0.32	$0.48	$0.45	$0.32	$0.57
Weighted Average Basic Shares Outstanding	157.37M	158.43M	158.53M	157.71M	157.31M	157.53M	158.13M	157.18M	157.31M	157.01M	156.93M
Diluted Earnings per Share	$0.14	$0.22	$0.21	$0.26	$0.31	$0.17	$0.31	$0.48	$0.43	$0.31	$0.55
Weighted Average Diluted Shares Outstanding	158.94M	160.63M	161.12M	160.77M	160.50M	160.06M	161.94M	161.86M	161.62M	161.75M	162.17M
Weighted Average Basic & Diluted Shares Outstanding	156.77M	158.09M	158.89M	158.60M	157.58M	157.19M	158.15M	158.17M	157.44M	157.28M	39.24M
Cash Dividends to Common per Share	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.32

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Net Change in Cash & Equivalents	-29	8.00	-27	52	46	-21	32	27	9.71	-264
Net Cash From Operating Activities	299	254	325	352	205	182	170	144	144	139
Net Cash From Continuing Operating Activities	299	254	325	352	205	182	170	144	144	139
Net Income / (Loss) Continuing Operations	168	285	263	140	229	96	126	76	104	108
Consolidated Net Income / (Loss)	168	285	263	140	229	96	126	76	104	108
Depreciation Expense	112	107	101	88	83	78	64	60	43	37
Non-Cash Adjustments To Reconcile Net Income	68	-19	26	124	-113	46	50	36	15	4.46
Changes in Operating Assets and Liabilities, net	-49	-120	-65	1.03	6.19	-39	-71	-28	-18	-10
Net Cash From Investing Activities	-203	-266	-97	-244	27	-337	-39	-306	-108	-426
Net Cash From Continuing Investing Activities	-203	-266	-97	-244	27	-337	-39	-306	-108	-426
Purchase of Property, Plant & Equipment	-63	-38	-45	-44	-52	-25	-21	-15	-17	-20
Acquisitions	-170	-101	0.00	-225	0.00	-289	-68	-254	-91	-420
Purchase of Investments	-5.53	-21	-78	-40	-68	-43	-8.57	-43	0.00	0.00
Divestitures	0.00	18	0.00	0.00	-	-	-	-	-	-
Sale and/or Maturity of Investments	28	108	26	66	147	22	58	6.08	0.78	13
Other Investing Activities, net	7.00	-232	0.00	-	-	0.00	0.68	0.00	-0.03	0.05
Net Cash From Financing Activities	-122	23	-243	-63	-184	134	-99	189	-23	31
Net Cash From Continuing Financing Activities	-122	23	-243	-63	-184	134	-99	189	-23	31
Repayment of Debt	-256	-528	-175	-272	-189	-420	-63	-118	-59	-95
Repurchase of Common Equity	-80	-20	-161	-43	-50	-15	0.00	0.00	-	-
Payment of Dividends	-50	-50	-50	-50	-49	-48	-48	-47	-48	-47
Issuance of Debt	225	620	90	256	40	580	55	369	77	163
Other Financing Activities, net	39	0.92	53	46	64	38	-43	-15	6.02	10
Effect of Exchange Rate Changes	-2.33	-3.36	-12	6.37	-	-0.31	-	0.50	-3.51	-8.18
Cash Interest Paid	15	8.37	11	-	-	-	-	-	-	-

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-37	-9.99	36	12	9.78	-19	-32	53	-37	-0.58	-7.31
Net Cash From Operating Activities	41	84	64	75	81	83	59	83	51	64	56
Net Cash From Continuing Operating Activities	41	84	64	75	81	83	59	83	51	64	56
Net Income / (Loss) Continuing Operations	23	35	34	41	49	27	51	75	70	50	90
Consolidated Net Income / (Loss)	23	35	34	41	49	27	51	75	70	50	90
Depreciation Expense	28	27	28	28	27	28	29	27	27	27	27
Non-Cash Adjustments To Reconcile Net Income	8.64	18	17	26	11	20	11	-1.39	8.84	6.51	-33
Changes in Operating Assets and Liabilities, net	-18	3.68	-14	-20	-6.09	8.13	-31	-18	-55	-19	-28
Net Cash From Investing Activities	-8.87	-5.03	-22	-8.81	-16	-24	-154	-4.76	-241	-0.11	-20
Net Cash From Continuing Investing Activities	-8.87	-5.03	-22	-8.81	-16	-24	-154	-4.76	-241	-0.11	-20
Purchase of Property, Plant & Equipment	-10	-6.82	-9.17	-18	-16	-15	-14	-11	-12	-6.11	-9.56
Sale and/or Maturity of Investments	1.25	-	2.49	2.18	-	-	26	6.08	2.65	12	88
Net Cash From Financing Activities	-68	-84	-12	-60	-52	-81	72	-24	151	-72	-32
Net Cash From Continuing Financing Activities	-68	-84	-12	-60	-52	-81	72	-24	151	-72	-32
Repayment of Debt	-8.00	-	-19	-70	-58	-58	-70	-20	-	-65	-443
Repurchase of Common Equity	-100	-	-	-	-	-	-	-	-	-	-20
Payment of Dividends	-13	-13	-13	-13	-13	-13	-13	-13	-13	-13	-13
Issuance of Debt	38	-	0.00	-	-	65	160	-	170	-	450
Other Financing Activities, net	15	4.53	20	23	18	4.20	-5.83	8.38	-6.58	5.03	-5.90
Effect of Exchange Rate Changes	-1.08	-5.47	5.12	5.28	-2.35	3.42	-8.69	-1.13	2.32	7.35	-12
Cash Interest Paid	4.40	4.63	5.21	2.11	3.81	4.08	4.51	2.60	0.15	2.21	3.41
Cash Income Taxes Paid	18	21	16	-	7.20	4.85	33	-	36	12	15

This table presents Bio-Techne's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Total Assets	2,704	2,639	2,295	2,263	2,028	1,884	1,593	1,558	1,130	1,063
Total Current Assets	617	621	606	511	521	413	398	348	254	248
Cash & Equivalents	152	181	173	199	147	101	122	92	64	55
Short-Term Investments	1.07	24	74	32	124	65	60	66	32	56
Accounts Receivable	241	218	195	145	123	137	120	117	93	70
Inventories, net	180	172	141	117	103	91	86	60	57	50
Other Current Assets	34	27	23	17	24	18	11	13	7.56	6.24
Other Current Nonoperating Assets	9.77	0.00	-	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	251	226	223	208	177	154	145	135	132	130
Total Noncurrent Assets	1,835	1,791	1,466	1,544	1,330	1,318	1,049	1,075	743	685
Goodwill	973	873	822	843	728	733	598	579	431	391
Intangible Assets	507	535	532	616	517	579	446	452	311	293
Other Noncurrent Operating Assets	356	384	112	85	85	5.67	5.27	44	1.92	1.85
Total Liabilities & Shareholders' Equity	2,704	2,639	2,295	2,263	2,028	1,884	1,593	1,558	1,130	1,063
Total Liabilities	635	672	589	692	646	719	514	609	250	216
Total Current Liabilities	159	129	176	152	107	102	80	136	54	40
Accounts Payable	38	26	34	29	23	16	18	17	21	13
Accrued Expenses	25	15	18	15	9.09	26	20	19	8.37	6.60
Current Deferred Revenue	28	23	23	-	-	9.08	-	5.97	4.72	3.38
Current Deferred & Payable Income Tax Liabilities	3.71	12	13	5.34	2.38	5.76	8.88	2.48	1.78	1.97
Current Employee Benefit Liabilities	50	37	62	51	31	29	24	27	15	10
Other Current Liabilities	15	13	13	34	23	0.00	8.11	-	-	-
Total Noncurrent Liabilities	476	544	413	539	540	617	435	473	196	177
Long-Term Debt	319	350	243	329	344	493	339	344	92	73
Noncurrent Deferred & Payable Income Tax Liabilities	56	89	99	93	101	90	86	121	63	61
Other Noncurrent Operating Liabilities	101	105	70	117	94	34	9.34	8.70	42	42
Total Equity & Noncontrolling Interests	2,069	1,967	1,701	1,571	1,381	1,166	1,079	950	879	847
Total Preferred & Common Equity	2,069	1,967	1,702	1,563	1,381	1,166	1,079	950	879	847
Total Common Equity	2,069	1,967	1,702	1,563	1,381	1,166	1,079	950	879	847
Common Stock	822	723	654	535	421	317	247	200	179	164
Retained Earnings	1,325	1,309	1,123	1,085	1,057	932	877	799	771	714
Accumulated Other Comprehensive Income / (Loss)	-78	-66	-75	-57	-97	-84	-45	-49	-70	-31

This table presents Bio-Techne's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	2,644	2,670	2,736	2,704	2,721	2,731	2,755	2,639	2,600	2,363	2,351
Total Current Assets	627	635	649	617	611	591	591	621	571	565	552
Cash & Equivalents	141	178	188	152	140	130	149	181	127	165	165
Short-Term Investments	0.00	0.00	0.00	1.07	5.40	5.52	0.00	24	30	32	38
Accounts Receivable	237	218	224	241	228	207	205	218	216	185	174
Inventories, net	191	188	185	180	179	181	186	172	169	160	150
Other Current Assets	54	50	43	34	31	40	52	27	28	23	25
Other Current Nonoperating Assets	4.70	1.05	9.46	9.77	27	27	-	0.00	-	-	-
Plant, Property, & Equipment, net	252	250	254	251	244	234	232	226	224	224	224
Total Noncurrent Assets	1,765	1,786	1,834	1,835	1,867	1,906	1,932	1,791	1,805	1,574	1,575
Goodwill	969	965	983	973	971	980	969	873	871	870	865
Intangible Assets	444	461	486	507	526	551	579	535	553	568	586
Other Noncurrent Operating Assets	353	360	365	356	369	375	384	384	381	137	124
Total Liabilities & Shareholders' Equity	2,644	2,670	2,736	2,704	2,721	2,731	2,755	2,639	2,600	2,363	2,351
Total Liabilities	626	592	597	635	707	767	758	672	710	536	600
Total Current Liabilities	169	161	142	159	150	135	128	129	141	128	138
Accounts Payable	32	33	32	38	29	32	28	26	27	24	30
Accrued Expenses	24	28	21	25	18	17	16	15	16	16	14
Current Deferred Revenue	32	28	27	28	30	28	25	23	25	-	-
Current Deferred & Payable Income Tax Liabilities	3.63	3.14	3.14	3.71	12	6.65	5.94	12	18	25	17
Current Employee Benefit Liabilities	62	54	42	50	44	33	35	37	39	29	33
Other Current Liabilities	16	16	18	15	16	17	17	13	12	34	36
Total Noncurrent Liabilities	457	431	455	476	557	632	630	544	569	408	462
Long-Term Debt	330	300	300	319	389	447	440	350	370	200	265
Noncurrent Deferred & Payable Income Tax Liabilities	32	38	50	56	64	72	83	89	95	111	113
Other Noncurrent Operating Liabilities	95	93	105	101	104	113	107	105	104	97	84
Total Equity & Noncontrolling Interests	2,018	2,078	2,139	2,069	2,014	1,964	1,998	1,967	1,890	1,827	1,751
Total Preferred & Common Equity	2,018	2,078	2,139	2,069	2,014	1,964	1,998	1,967	1,890	1,827	1,751
Total Common Equity	2,018	2,078	2,139	2,069	2,014	1,964	1,998	1,967	1,890	1,827	1,751
Common Stock	904	877	858	822	792	766	748	723	717	702	680
Retained Earnings	1,196	1,287	1,341	1,325	1,298	1,261	1,328	1,309	1,247	1,200	1,163
Accumulated Other Comprehensive Income / (Loss)	-82	-86	-60	-78	-75	-64	-78	-66	-74	-75	-92

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.97%	2.81%	18.75%	26.04%	3.46%	11.04%	14.21%	12.82%	10.34%	26.41%
EBITDA Growth	-31.71%	9.86%	65.58%	-33.99%	78.78%	5.56%	11.81%	-6.62%	-0.29%	8.10%
EBIT Growth	-42.82%	11.08%	92.94%	-45.21%	121.60%	-1.90%	14.04%	-20.11%	-3.93%	-2.29%
NOPAT Growth	-25.74%	-2.68%	15.82%	71.22%	3.75%	-7.74%	66.44%	-23.19%	3.83%	-6.44%
Net Income Growth	-41.11%	8.49%	88.49%	-39.12%	138.67%	-23.84%	65.80%	-27.17%	-3.03%	-2.90%
EPS Growth	-40.34%	6.02%	88.49%	-39.12%	135.63%	-25.38%	63.05%	-27.50%	-3.11%	-3.67%
Operating Cash Flow Growth	17.53%	-21.79%	-7.64%	71.61%	12.99%	6.60%	18.54%	-0.30%	3.44%	1.90%
Free Cash Flow Firm Growth	152.14%	-164.99%	1,889.38%	-93.05%	213.51%	-244.71%	142.01%	-685.47%	114.68%	-466.62%
Invested Capital Growth	5.18%	23.37%	1.77%	14.39%	-2.33%	21.99%	2.96%	36.65%	8.08%	88.71%
Revenue Q/Q Growth	0.41%	1.17%	2.71%	9.81%	-2.10%	1.62%	3.82%	4.03%	3.55%	5.89%
EBITDA Q/Q Growth	-15.34%	15.99%	7.41%	-14.61%	10.94%	-8.39%	13.33%	5.74%	0.67%	3.54%
EBIT Q/Q Growth	-22.43%	21.57%	9.59%	-22.29%	13.98%	-14.25%	18.46%	4.97%	0.08%	1.56%
NOPAT Q/Q Growth	-16.14%	7.12%	-3.28%	18.45%	2.90%	3.11%	-1.82%	2.63%	1.14%	-0.38%
Net Income Q/Q Growth	-17.19%	4.99%	21.90%	-24.05%	22.68%	-20.81%	12.58%	2.67%	-0.67%	-0.46%
EPS Q/Q Growth	-18.60%	2.33%	21.90%	-24.05%	19.26%	-21.09%	11.45%	2.53%	-0.71%	-0.69%
Operating Cash Flow Q/Q Growth	-2.57%	-7.06%	-5.60%	28.09%	-5.16%	-4.67%	8.95%	10.96%	-0.34%	-0.56%
Free Cash Flow Firm Q/Q Growth	-21.44%	-13.32%	1,122.05%	-92.46%	1.13%	-56.55%	24.74%	77.41%	-95.14%	8.80%
Invested Capital Q/Q Growth	-0.31%	0.38%	-1.51%	12.92%	1.15%	1.00%	-3.25%	-1.56%	1,040.74%	-0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.41%	67.72%	68.42%	67.97%	65.41%	66.31%	67.21%	66.53%	67.46%	67.94%
EBITDA Margin	26.73%	39.91%	37.35%	26.79%	51.15%	29.60%	31.13%	31.80%	38.42%	42.52%
Operating Margin	17.83%	26.30%	26.83%	25.49%	21.31%	20.55%	21.18%	21.42%	30.18%	32.51%
EBIT Margin	17.09%	30.48%	28.21%	17.36%	39.94%	18.65%	21.11%	21.14%	29.85%	34.29%
Profit (Net Income) Margin	14.50%	25.11%	23.80%	14.99%	31.04%	13.46%	19.62%	13.51%	20.94%	23.82%
Tax Burden Percent	90.53%	84.29%	87.30%	94.20%	82.93%	85.77%	100.16%	67.96%	70.84%	69.88%
Interest Burden Percent	93.73%	97.75%	96.63%	91.66%	93.70%	84.13%	92.80%	94.07%	98.99%	99.41%
Effective Tax Rate	9.47%	15.71%	12.70%	5.80%	17.07%	14.23%	-0.16%	32.04%	29.16%	30.12%
Return on Invested Capital (ROIC)	8.62%	13.16%	15.23%	14.16%	8.76%	9.17%	11.19%	7.88%	12.61%	16.52%
ROIC Less NNEP Spread (ROIC-NNEP)	-3.82%	54.21%	21.79%	-67.53%	54.23%	-2.74%	6.18%	3.20%	25.40%	14.02%
Return on Net Nonoperating Assets (RNNOA)	-0.29%	2.41%	0.85%	-4.70%	9.25%	-0.61%	1.24%	0.44%	-0.51%	-3.40%
Return on Equity (ROE)	8.33%	15.57%	16.08%	9.46%	18.01%	8.56%	12.44%	8.32%	12.10%	13.12%
Cash Return on Invested Capital (CROIC)	3.58%	-7.77%	13.47%	0.73%	11.12%	-10.64%	8.28%	-23.10%	4.85%	-44.93%
Operating Return on Assets (OROA)	7.42%	14.05%	13.69%	7.54%	15.09%	7.66%	8.61%	8.86%	13.59%	16.10%
Return on Assets (ROA)	6.29%	11.57%	11.55%	6.51%	11.72%	5.53%	8.01%	5.66%	9.53%	11.19%
Return on Common Equity (ROCE)	8.33%	15.57%	16.04%	9.43%	18.01%	8.56%	12.44%	8.32%	12.10%	13.12%
Return on Equity Simple (ROE_SIMPLE)	8.13%	14.52%	15.46%	8.93%	16.60%	8.24%	11.69%	8.01%	11.88%	12.72%
Net Operating Profit after Tax (NOPAT)	187	252	259	224	131	126	136	82	107	103
NOPAT Margin	16.14%	22.17%	23.42%	24.01%	17.67%	17.62%	21.21%	14.56%	21.38%	22.72%
Net Nonoperating Expense Percent (NNEP)	12.44%	-41.05%	-6.56%	81.68%	-45.47%	11.91%	5.02%	4.68%	-12.79%	2.51%
Cost of Revenue to Revenue	33.59%	32.28%	31.58%	32.03%	34.59%	33.69%	32.79%	33.47%	32.54%	32.06%
SG&A Expenses to Revenue	40.24%	33.29%	33.72%	34.90%	35.28%	37.02%	37.42%	35.60%	28.23%	26.40%
R&D to Revenue	8.34%	8.14%	7.88%	7.58%	8.83%	8.74%	8.60%	9.51%	9.06%	9.03%
Operating Expenses to Revenue	48.58%	41.42%	41.60%	42.49%	44.10%	45.77%	46.03%	45.11%	37.29%	35.44%
Earnings before Interest and Taxes (EBIT)	198	346	312	162	295	133	136	119	149	155
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	310	454	413	249	378	211	200	179	192	192
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.45	6.50	7.91	11.05	7.18	6.60	5.00	4.44	4.53	4.05
Price to Tangible Book Value (P/TBV)	19.15	22.86	38.66	166.23	72.76	0.00	154.81	0.00	28.89	20.96
Price to Revenue (P/Rev)	9.73	11.24	12.17	18.56	13.43	10.77	8.39	7.49	7.98	7.58
Price to Earnings (P/E)	67.09	44.80	49.47	123.05	43.26	80.06	42.76	55.40	38.13	31.80
Dividend Yield	0.45%	0.49%	0.37%	0.29%	0.49%	0.63%	0.89%	1.13%	1.20%	1.38%
Earnings Yield	1.49%	2.23%	2.02%	0.81%	2.31%	1.25%	2.34%	1.81%	2.62%	3.14%
Enterprise Value to Invested Capital (EV/IC)	5.14	6.11	7.85	10.33	6.80	5.33	4.49	3.72	4.53	4.17
Enterprise Value to Revenue (EV/Rev)	9.87	11.37	12.18	18.69	13.55	11.25	8.63	7.93	7.98	7.50
Enterprise Value to EBITDA (EV/EBITDA)	36.94	28.50	32.61	69.76	26.50	38.02	27.73	24.94	20.77	17.64
Enterprise Value to EBIT (EV/EBIT)	57.77	37.32	43.18	107.63	33.93	60.34	40.90	37.53	26.74	21.87
Enterprise Value to NOPAT (EV/NOPAT)	61.17	51.31	52.01	77.84	76.68	63.85	40.70	54.50	37.34	33.02
Enterprise Value to Operating Cash Flow (EV/OCF)	38.28	50.82	41.40	49.41	48.79	44.24	32.58	31.08	27.63	24.34
Enterprise Value to Free Cash Flow (EV/FCFF)	147.48	0.00	58.80	1,511.35	60.42	0.00	55.03	0.00	97.11	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.15	0.18	0.15	0.22	0.26	0.44	0.31	0.43	0.11	0.09
Long-Term Debt to Equity	0.15	0.18	0.14	0.21	0.25	0.42	0.31	0.36	0.10	0.09
Financial Leverage	0.08	0.04	0.04	0.07	0.17	0.22	0.20	0.14	-0.02	-0.24
Leverage Ratio	1.32	1.35	1.39	1.45	1.54	1.55	1.55	1.47	1.27	1.17
Compound Leverage Factor	1.24	1.31	1.35	1.33	1.44	1.30	1.44	1.38	1.26	1.17
Debt to Total Capital	13.36%	15.24%	13.08%	18.02%	20.80%	30.38%	23.91%	30.10%	9.77%	8.34%
Short-Term Debt to Total Capital	0.00%	0.15%	0.64%	0.86%	1.06%	0.95%	0.00%	4.79%	0.39%	0.44%
Long-Term Debt to Total Capital	13.36%	15.09%	12.44%	17.16%	19.74%	29.43%	23.91%	25.31%	9.39%	7.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	-0.04%	0.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.64%	84.76%	86.96%	81.55%	79.20%	69.62%	76.09%	69.90%	90.23%	91.66%
Debt to EBITDA	1.03	0.78	0.62	1.38	0.96	2.41	1.69	2.28	0.50	0.40
Net Debt to EBITDA	0.54	0.33	0.02	0.46	0.24	1.62	0.79	1.40	0.00	-0.18
Long-Term Debt to EBITDA	1.03	0.77	0.59	1.32	0.91	2.33	1.69	1.92	0.48	0.38
Debt to NOPAT	1.70	1.40	0.99	1.54	2.78	4.04	2.49	4.99	0.89	0.75
Net Debt to NOPAT	0.89	0.59	0.03	0.51	0.70	2.72	1.15	3.06	-0.01	-0.33
Long-Term Debt to NOPAT	1.70	1.39	0.94	1.47	2.64	3.92	2.49	4.20	0.86	0.71
Altman Z-Score	12.22	13.19	15.55	16.50	11.03	7.92	7.99	5.65	11.59	11.58
Noncontrolling Interest Sharing Ratio	0.00%	-0.02%	0.23%	0.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.87	4.84	3.44	3.35	4.88	4.05	5.01	2.57	4.69	6.24
Quick Ratio	2.47	3.29	2.51	2.48	3.69	2.98	3.80	2.03	3.49	4.55
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	78	-149	229	12	166	-146	101	-240	41	-279
Operating Cash Flow to CapEx	475.50%	665.18%	724.31%	794.93%	396.60%	714.73%	813.83%	946.84%	853.10%	700.12%
Free Cash Flow to Firm to Interest Expense	4.93	-13.27	20.25	0.83	8.63	-6.73	9.90	-32.62	23.46	-181.00
Operating Cash Flow to Interest Expense	19.00	22.68	28.76	25.24	10.69	8.37	16.72	19.52	82.47	90.26
Operating Cash Flow Less CapEx to Interest Expense	15.00	19.27	24.79	22.07	7.99	7.20	14.67	17.46	72.80	77.37
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.46	0.49	0.43	0.38	0.41	0.41	0.42	0.46	0.47
Accounts Receivable Turnover	5.04	5.50	6.50	6.95	5.68	5.54	5.42	5.36	6.11	7.23
Inventory Turnover	2.22	2.35	2.71	2.71	2.63	2.72	2.89	3.21	3.04	3.28
Fixed Asset Turnover	4.86	5.06	5.13	4.84	4.47	4.77	4.59	4.21	3.81	3.66
Accounts Payable Turnover	12.23	12.32	11.04	11.36	13.00	13.88	11.94	10.05	9.52	12.55
Days Sales Outstanding (DSO)	72.41	66.31	56.11	52.52	64.24	65.88	67.30	68.14	59.77	50.46
Days Inventory Outstanding (DIO)	164.70	155.58	134.81	134.59	138.72	134.08	126.20	113.54	119.91	111.32
Days Payable Outstanding (DPO)	29.83	29.62	33.06	32.12	28.07	26.30	30.56	36.32	38.32	29.07
Cash Conversion Cycle (CCC)	207.28	192.27	157.85	154.99	174.88	173.66	162.94	145.37	141.35	132.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,225	2,116	1,715	1,685	1,473	1,508	1,236	1,201	879	813
Invested Capital Turnover	0.53	0.59	0.65	0.59	0.50	0.52	0.53	0.54	0.59	0.73
Increase / (Decrease) in Invested Capital	110	401	30	212	-35	272	36	322	66	382
Enterprise Value (EV)	11,445	12,929	13,467	17,399	10,012	8,034	5,551	4,466	3,983	3,392
Market Capitalization	11,279	12,780	13,458	17,277	9,920	7,692	5,394	4,215	3,984	3,426
Book Value per Share	$13.13	$12.49	$43.38	$40.19	$36.14	$30.86	$28.72	$25.44	$23.63	$22.80
Tangible Book Value per Share	$3.74	$3.55	$8.87	$2.67	$3.57	($3.88)	$0.93	($2.18)	$3.70	$4.40
Total Capital	2,388	2,320	1,957	1,917	1,744	1,674	1,418	1,358	975	924
Total Debt	319	354	256	345	363	509	339	409	95	77
Total Long-Term Debt	319	350	243	329	344	493	339	344	92	73
Net Debt	166	149	8.88	114	92	343	157	251	-0.58	-34
Capital Expenditures (CapEx)	63	38	45	44	52	25	21	15	17	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	305	292	195	143	162	160	137	120	108	102
Debt-free Net Working Capital (DFNWC)	458	496	442	375	433	327	319	278	204	213
Net Working Capital (NWC)	458	493	430	358	414	311	319	213	200	209
Net Nonoperating Expense (NNE)	19	-33	-4.19	84	-99	30	10	5.86	2.20	-4.99
Net Nonoperating Obligations (NNO)	156	149	14	114	92	343	157	251	-0.58	-34
Total Depreciation and Amortization (D&A)	112	107	101	88	83	78	64	60	43	37
Debt-free, Cash-free Net Working Capital to Revenue	26.33%	25.70%	17.64%	15.39%	21.90%	22.48%	21.32%	21.29%	21.58%	22.47%
Debt-free Net Working Capital to Revenue	39.52%	43.68%	39.98%	40.26%	58.58%	45.73%	49.59%	49.31%	40.78%	47.00%
Net Working Capital to Revenue	39.52%	43.37%	38.85%	38.49%	56.08%	43.50%	49.59%	37.74%	40.03%	46.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.07	$1.81	$1.73	$0.91	$1.50	$0.64	$0.84	$0.51	$0.70	$0.73
Adjusted Weighted Average Basic Shares Outstanding	157.71M	157.18M	156.88M	154.99M	152.80M	151.12M	149.90M	149.25M	148.78M	148.38M
Adjusted Diluted Earnings per Share	$1.05	$1.76	$1.66	$0.87	$1.46	$0.62	$0.83	$0.51	$0.70	$0.72
Adjusted Weighted Average Diluted Shares Outstanding	160.77M	161.86M	164.12M	161.93M	157.60M	155.57M	152.22M	150M	149.30M	148.92M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	158.60M	158.17M	156.85M	156.32M	154.20M	152.25M	150.93M	149.53M	149.19M	148.67M
Normalized Net Operating Profit after Tax (NOPAT)	187	252	259	224	131	126	95	82	107	103
Normalized NOPAT Margin	16.14%	22.17%	23.42%	24.01%	17.67%	17.62%	14.83%	14.56%	21.38%	22.72%
Pre Tax Income Margin	16.02%	29.79%	27.26%	15.92%	37.43%	15.69%	19.59%	19.89%	29.55%	34.09%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	12.59	30.89	27.58	11.59	15.37	6.13	13.32	16.17	85.23	100.44
NOPAT to Interest Expense	11.89	22.47	22.89	16.02	6.80	5.80	13.39	11.13	61.03	66.55
EBIT Less CapEx to Interest Expense	8.59	27.48	23.61	8.41	12.68	4.96	11.27	14.11	75.56	87.54
NOPAT Less CapEx to Interest Expense	7.90	19.06	18.92	12.85	4.11	4.63	11.33	9.07	51.36	53.65
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	29.99%	17.62%	19.07%	35.55%	21.33%	50.34%	38.03%	62.20%	45.57%	43.72%
Augmented Payout Ratio	77.61%	24.47%	80.25%	66.48%	43.18%	66.38%	38.03%	62.20%	45.57%	43.72%

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.20%	8.96%	4.52%	1.59%	3.16%	0.37%	2.70%	4.54%	1.30%	0.86%	4.63%
EBITDA Growth	-29.72%	14.33%	-12.54%	-39.17%	-12.01%	-35.31%	-5.86%	14.10%	-7.45%	8.17%	-5.68%
EBIT Growth	-42.23%	28.42%	-18.94%	-51.52%	-16.47%	-50.82%	-12.00%	17.32%	-11.32%	8.89%	-10.92%
NOPAT Growth	-57.55%	23.43%	-41.81%	-44.74%	-23.38%	-38.83%	17.97%	28.02%	-11.21%	-1.97%	-24.72%
Net Income Growth	-53.96%	27.03%	-34.11%	-46.23%	-30.13%	-45.08%	-43.17%	21.92%	16.75%	-30.61%	30.09%
EPS Growth	-54.84%	29.41%	-32.26%	-45.83%	-27.91%	-45.16%	-43.64%	23.08%	16.22%	-36.73%	30.09%
Operating Cash Flow Growth	-49.23%	1.48%	7.59%	-9.47%	60.26%	29.09%	5.89%	-18.81%	-30.90%	-36.25%	15.79%
Free Cash Flow Firm Growth	174.11%	122.81%	120.00%	79.73%	76.20%	-442.42%	-661.01%	-1,063.31%	-74.46%	58.17%	68.26%
Invested Capital Growth	-1.32%	-2.22%	-2.15%	5.18%	5.90%	22.92%	25.86%	23.37%	21.05%	7.18%	6.00%
Revenue Q/Q Growth	6.45%	2.62%	-5.44%	0.88%	11.31%	-1.57%	-8.09%	2.44%	8.31%	0.71%	-6.44%
EBITDA Q/Q Growth	-5.26%	2.42%	-7.54%	-21.66%	43.31%	-21.65%	-35.69%	13.31%	13.31%	14.03%	-22.06%
EBIT Q/Q Growth	-9.72%	6.73%	-12.33%	-31.61%	76.29%	-32.63%	-47.57%	17.85%	18.15%	20.55%	-30.10%
NOPAT Q/Q Growth	-40.80%	15.37%	-25.08%	-17.03%	72.12%	-45.61%	-28.85%	15.03%	37.42%	4.89%	-22.79%
Net Income Q/Q Growth	-35.26%	3.84%	-17.22%	-17.27%	78.62%	-46.14%	-32.45%	7.50%	40.42%	-44.27%	44.93%
EPS Q/Q Growth	-36.36%	4.76%	-19.23%	-16.13%	82.35%	-45.16%	-35.42%	11.63%	38.71%	-43.64%	44.93%
Operating Cash Flow Q/Q Growth	-51.25%	32.02%	-15.37%	-6.78%	-2.56%	39.97%	-28.79%	65.02%	-21.51%	14.81%	-45.40%
Free Cash Flow Firm Q/Q Growth	-40.96%	7.16%	227.38%	8.04%	81.83%	6.04%	-29.12%	-7.99%	-314.03%	-31.82%	-263.44%
Invested Capital Q/Q Growth	0.13%	-1.86%	0.74%	-0.31%	-0.79%	-1.79%	8.28%	0.38%	15.16%	0.56%	6.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.86%	65.27%	63.23%	66.43%	67.43%	64.78%	66.87%	67.93%	68.73%	67.52%	66.60%
EBITDA Margin	20.96%	23.55%	23.60%	24.14%	31.08%	22.45%	28.20%	40.31%	36.44%	34.83%	30.76%
Operating Margin	12.24%	15.96%	13.81%	14.97%	22.08%	13.94%	20.17%	31.37%	27.27%	25.00%	20.88%
EBIT Margin	12.24%	14.43%	13.88%	14.97%	22.08%	12.25%	17.90%	31.37%	27.27%	25.00%	20.88%
Profit (Net Income) Margin	7.14%	11.75%	11.61%	13.26%	16.17%	10.08%	18.41%	25.05%	23.87%	18.41%	33.28%
Tax Burden Percent	59.02%	81.37%	83.64%	97.43%	80.31%	82.26%	102.90%	85.47%	87.56%	75.28%	86.52%
Interest Burden Percent	98.88%	100.00%	100.00%	90.92%	91.17%	100.00%	100.00%	93.43%	99.98%	97.85%	184.16%
Effective Tax Rate	40.98%	18.63%	16.36%	2.57%	19.69%	17.74%	-2.90%	14.53%	12.44%	24.72%	13.48%
Return on Invested Capital (ROIC)	3.94%	6.98%	5.97%	7.79%	9.43%	6.44%	11.55%	15.91%	13.94%	11.91%	11.42%
ROIC Less NNEP Spread (ROIC-NNEP)	3.81%	5.17%	6.05%	5.13%	7.25%	3.81%	7.97%	9.41%	13.93%	-14.35%	70.36%
Return on Net Nonoperating Assets (RNNOA)	0.38%	0.52%	0.58%	0.39%	0.81%	0.29%	0.77%	0.42%	0.95%	-0.03%	2.88%
Return on Equity (ROE)	4.32%	7.50%	6.55%	8.18%	10.24%	6.73%	12.32%	16.33%	14.89%	11.88%	14.30%
Cash Return on Invested Capital (CROIC)	7.59%	9.91%	9.37%	3.58%	4.55%	-8.83%	-10.31%	-7.77%	-6.83%	6.81%	7.94%
Operating Return on Assets (OROA)	5.52%	6.39%	5.92%	6.50%	9.58%	5.51%	8.02%	14.46%	12.51%	11.99%	10.10%
Return on Assets (ROA)	3.22%	5.20%	4.95%	5.75%	7.01%	4.53%	8.25%	11.54%	10.95%	8.83%	16.10%
Return on Common Equity (ROCE)	4.32%	7.50%	6.55%	8.18%	10.24%	6.73%	12.32%	16.33%	14.90%	11.88%	14.27%
Return on Equity Simple (ROE_SIMPLE)	6.52%	7.61%	7.05%	0.00%	10.08%	11.42%	12.35%	0.00%	14.39%	14.33%	16.21%
Net Operating Profit after Tax (NOPAT)	23	39	33	45	54	31	57	81	70	51	49
NOPAT Margin	7.23%	12.99%	11.55%	14.58%	17.73%	11.47%	20.76%	26.81%	23.88%	18.82%	18.07%
Net Nonoperating Expense Percent (NNEP)	0.13%	1.81%	-0.08%	2.65%	2.18%	2.62%	3.58%	6.51%	0.01%	26.26%	-58.94%
Return On Investment Capital (ROIC_SIMPLE)	0.97%	1.62%	-	-	-	1.30%	-	-	-	-	-
Cost of Revenue to Revenue	32.14%	34.73%	36.77%	33.57%	32.57%	35.22%	33.13%	32.07%	31.27%	32.48%	33.40%
SG&A Expenses to Revenue	47.84%	40.89%	41.17%	43.63%	36.86%	42.43%	38.03%	28.79%	33.74%	34.25%	36.85%
R&D to Revenue	7.77%	8.42%	8.25%	7.84%	8.49%	8.41%	8.67%	7.77%	7.72%	8.27%	8.86%
Operating Expenses to Revenue	55.62%	49.31%	49.41%	51.46%	45.35%	50.84%	46.70%	36.56%	41.46%	42.52%	45.72%
Earnings before Interest and Taxes (EBIT)	39	43	40	46	67	33	50	95	80	68	56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	66	70	68	74	94	61	78	121	107	95	83
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.59	5.51	5.93	5.45	5.48	6.19	5.36	6.50	6.13	7.07	6.30
Price to Tangible Book Value (P/TBV)	15.30	17.53	18.92	19.15	21.36	28.07	23.85	22.86	24.88	33.12	36.74
Price to Revenue (P/Rev)	7.67	9.57	10.82	9.73	9.57	10.61	9.37	11.24	10.32	11.53	9.87
Price to Earnings (P/E)	70.40	72.37	84.11	67.09	54.39	54.20	43.44	44.80	42.73	49.31	37.77
Dividend Yield	0.55%	0.44%	0.40%	0.45%	0.46%	0.42%	0.59%	0.49%	0.54%	0.00%	0.46%
Earnings Yield	1.42%	1.38%	1.19%	1.49%	1.84%	1.84%	2.30%	2.23%	2.34%	2.03%	2.65%
Enterprise Value to Invested Capital (EV/IC)	4.29	5.26	5.71	5.14	5.06	5.54	4.81	6.11	5.60	7.06	6.10
Enterprise Value to Revenue (EV/Rev)	7.82	9.67	10.92	9.87	9.78	10.88	9.62	11.37	10.51	11.53	9.93
Enterprise Value to EBITDA (EV/EBITDA)	33.45	37.46	42.63	36.94	30.84	32.89	27.01	28.50	30.19	32.30	28.27
Enterprise Value to EBIT (EV/EBIT)	55.01	58.36	67.77	57.77	44.19	46.40	36.89	37.32	41.44	43.74	38.31
Enterprise Value to NOPAT (EV/NOPAT)	68.09	67.87	78.41	61.17	50.58	52.05	42.54	51.31	50.21	53.13	45.58
Enterprise Value to Operating Cash Flow (EV/OCF)	35.71	37.96	42.14	38.28	36.78	45.08	42.73	50.82	43.15	43.58	33.34
Enterprise Value to Free Cash Flow (EV/FCFF)	56.19	52.49	60.24	147.48	114.24	0.00	0.00	0.00	0.00	107.27	79.02
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.14	0.14	0.15	0.19	0.23	0.22	0.18	0.20	0.11	0.16
Long-Term Debt to Equity	0.16	0.14	0.14	0.15	0.19	0.23	0.22	0.18	0.20	0.11	0.15
Financial Leverage	0.10	0.10	0.10	0.08	0.11	0.08	0.10	0.04	0.07	0.00	0.04
Leverage Ratio	1.33	1.34	1.33	1.32	1.36	1.34	1.36	1.35	1.36	1.32	1.36
Compound Leverage Factor	1.32	1.34	1.33	1.20	1.24	1.34	1.36	1.26	1.36	1.29	2.50
Debt to Total Capital	14.05%	12.61%	12.30%	13.36%	16.19%	18.54%	18.11%	15.24%	16.57%	9.87%	13.45%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.07%	0.15%	0.23%	0.00%	0.37%
Long-Term Debt to Total Capital	14.05%	12.61%	12.30%	13.36%	16.19%	18.54%	18.04%	15.09%	16.34%	9.87%	13.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	85.95%	87.39%	87.70%	86.64%	83.81%	81.46%	81.89%	84.76%	83.43%	90.13%	86.55%
Debt to EBITDA	1.17	0.97	1.00	1.03	1.06	1.18	1.08	0.78	0.96	0.50	0.69
Net Debt to EBITDA	0.67	0.40	0.37	0.54	0.67	0.82	0.72	0.33	0.56	0.01	0.18
Long-Term Debt to EBITDA	1.17	0.97	1.00	1.03	1.06	1.18	1.08	0.77	0.95	0.50	0.67
Debt to NOPAT	2.38	1.76	1.84	1.70	1.74	1.87	1.71	1.40	1.60	0.82	1.12
Net Debt to NOPAT	1.36	0.72	0.69	0.89	1.09	1.30	1.13	0.59	0.93	0.01	0.28
Long-Term Debt to NOPAT	2.38	1.76	1.84	1.70	1.74	1.87	1.70	1.39	1.57	0.82	1.09
Altman Z-Score	10.23	12.99	14.12	12.03	10.75	10.81	9.84	12.88	11.20	15.95	12.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.02%	-0.03%	-0.01%	0.22%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.71	3.94	4.56	3.87	4.08	4.37	4.63	4.84	4.04	4.40	4.01
Quick Ratio	2.23	2.45	2.89	2.47	2.49	2.54	2.76	3.29	2.65	2.97	2.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	52	89	83	-65	-71	-388	-413	-320	-296	-72	-54
Operating Cash Flow to CapEx	406.20%	1,236.56%	696.57%	419.89%	492.59%	559.18%	436.90%	769.95%	430.16%	1,053.92%	586.87%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.44	0.43	0.43	0.43	0.45	0.45	0.46	0.46	0.48	0.48
Accounts Receivable Turnover	5.20	5.62	5.47	5.04	5.20	5.84	6.04	5.50	5.37	6.63	6.95
Inventory Turnover	2.23	2.23	2.18	2.22	2.20	2.21	2.19	2.35	2.41	2.52	2.64
Fixed Asset Turnover	4.88	4.94	4.83	4.86	4.94	5.00	5.02	5.06	5.08	5.14	5.18
Accounts Payable Turnover	13.68	12.72	13.55	12.23	13.68	13.53	12.59	12.32	12.35	13.96	12.57
Days Sales Outstanding (DSO)	70.21	64.91	66.71	72.41	70.25	62.51	60.42	66.31	67.98	55.03	52.54
Days Inventory Outstanding (DIO)	163.37	163.88	167.63	164.70	166.19	165.39	166.42	155.58	151.72	144.99	138.45
Days Payable Outstanding (DPO)	26.69	28.69	26.94	29.83	26.68	26.97	29.00	29.62	29.54	26.14	29.05
Cash Conversion Cycle (CCC)	206.89	200.10	207.40	207.28	209.76	200.94	197.84	192.27	190.15	173.88	161.94
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,203	2,200	2,242	2,225	2,232	2,250	2,291	2,116	2,108	1,830	1,820
Invested Capital Turnover	0.55	0.54	0.52	0.53	0.53	0.56	0.56	0.59	0.58	0.63	0.63
Increase / (Decrease) in Invested Capital	-29	-50	-49	110	124	420	471	401	367	123	103
Enterprise Value (EV)	9,458	11,567	12,789	11,445	11,285	12,462	11,010	12,929	11,810	12,914	11,099
Market Capitalization	9,269	11,445	12,677	11,279	11,042	12,150	10,717	12,780	11,592	12,911	11,030
Book Value per Share	$12.77	$13.08	$13.48	$13.13	$12.81	$12.42	$12.63	$12.49	$12.02	$46.56	$44.66
Tangible Book Value per Share	$3.83	$4.11	$4.22	$3.74	$3.29	$2.74	$2.84	$3.55	$2.96	$9.93	$7.66
Total Capital	2,348	2,378	2,439	2,388	2,403	2,411	2,439	2,320	2,265	2,027	2,023
Total Debt	330	300	300	319	389	447	442	354	375	200	272
Total Long-Term Debt	330	300	300	319	389	447	440	350	370	200	265
Net Debt	189	122	112	166	244	311	293	149	218	3.24	69
Capital Expenditures (CapEx)	10	6.82	9.17	18	16	15	14	11	12	6.11	9.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	317	296	319	305	316	320	317	292	278	240	219
Debt-free Net Working Capital (DFNWC)	458	473	506	458	461	455	465	496	435	437	422
Net Working Capital (NWC)	458	473	506	458	461	455	464	493	430	437	414
Net Nonoperating Expense (NNE)	0.26	3.70	-0.15	4.05	4.75	3.80	6.49	5.31	0.01	1.10	-41
Net Nonoperating Obligations (NNO)	185	121	103	156	218	286	293	149	218	3.24	69
Total Depreciation and Amortization (D&A)	28	27	28	28	27	28	29	27	27	27	27
Debt-free, Cash-free Net Working Capital to Revenue	26.26%	24.74%	27.22%	26.33%	27.33%	27.93%	27.69%	25.70%	24.73%	21.43%	19.57%
Debt-free Net Working Capital to Revenue	37.89%	39.58%	43.23%	39.52%	39.92%	39.77%	40.69%	43.68%	38.72%	39.00%	37.74%
Net Working Capital to Revenue	37.89%	39.58%	43.23%	39.52%	39.92%	39.77%	40.54%	43.37%	38.25%	39.00%	37.08%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.14	$0.22	$0.21	$0.26	$0.31	$0.17	$0.32	$0.48	$0.45	$0.32	$0.57
Adjusted Weighted Average Basic Shares Outstanding	157.37M	158.43M	158.53M	157.71M	157.31M	157.53M	158.13M	157.18M	157.31M	157.01M	156.93M
Adjusted Diluted Earnings per Share	$0.14	$0.22	$0.21	$0.26	$0.31	$0.17	$0.31	$0.48	$0.43	$0.31	$0.55
Adjusted Weighted Average Diluted Shares Outstanding	158.94M	160.63M	161.12M	160.77M	160.50M	160.06M	161.94M	161.86M	161.62M	161.75M	162.17M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.26	$0.00	$0.00	$0.00	$0.48	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	156.77M	158.09M	158.89M	158.60M	157.58M	157.19M	158.15M	158.17M	157.44M	157.28M	156.97M
Normalized Net Operating Profit after Tax (NOPAT)	23	39	33	45	54	31	39	81	70	51	49
Normalized NOPAT Margin	7.23%	12.99%	11.55%	14.58%	17.73%	11.47%	14.12%	26.81%	23.88%	18.82%	18.07%
Pre Tax Income Margin	12.11%	14.43%	13.88%	13.61%	20.13%	12.25%	17.90%	29.31%	27.26%	24.46%	38.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	38.45%	32.02%	33.48%	29.99%	24.82%	22.48%	20.43%	17.62%	18.47%	19.18%	17.70%
Augmented Payout Ratio	171.88%	79.84%	33.48%	77.61%	64.25%	58.19%	20.43%	24.47%	47.30%	72.36%	81.29%

Frequently Asked Questions About Bio-Techne's Financials

When does Bio-Techne's fiscal year end?

According to the most recent income statement we have on file, Bio-Techne's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

How has Bio-Techne's net income changed over the last 9 years?

Bio-Techne's net income appears to be on an upward trend, with a most recent value of $168.11 million in 2024, rising from $107.74 million in 2015. The previous period was $285.44 million in 2023. See Bio-Techne's forecast for analyst expectations on what’s next for the company.

What is Bio-Techne's operating income?

Bio-Techne's total operating income in 2024 was $206.69 million, based on the following breakdown:

Total Gross Profit: $769.73 million
Total Operating Expenses: $563.04 million

How has Bio-Techne revenue changed over the last 9 years?

Over the last 9 years, Bio-Techne's total revenue changed from $452.25 million in 2015 to $1.16 billion in 2024, a change of 156.3%.

How much debt does Bio-Techne have?

Bio-Techne's total liabilities were at $635.02 million at the end of 2024, a 5.5% decrease from 2023, and a 193.4% increase since 2015.

How much cash does Bio-Techne have?

In the past 9 years, Bio-Techne's cash and equivalents has ranged from $54.53 million in 2015 to $199.09 million in 2021, and is currently $151.79 million as of their latest financial filing in 2024.

How has Bio-Techne's book value per share changed over the last 9 years?

Over the last 9 years, Bio-Techne's book value per share changed from 22.80 in 2015 to 13.13 in 2024, a change of -42.4%.

Related Companies

This page (NASDAQ:TECH) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Financials

Frequently Asked Questions About Bio-Techne's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Financials

Annual Income Statements for Bio-Techne

Quarterly Income Statements for Bio-Techne

Annual Cash Flow Statements for Bio-Techne

Quarterly Cash Flow Statements for Bio-Techne

Annual Balance Sheets for Bio-Techne

Quarterly Balance Sheets for Bio-Techne

Annual Metrics And Ratios for Bio-Techne

Quarterly Metrics And Ratios for Bio-Techne

Frequently Asked Questions About Bio-Techne's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools